济川药业(600566) - 2024 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2024 was ¥1,770,734,301.23, a decrease of 7.18% compared to the same period last year[2]. - The net profit attributable to shareholders for Q3 2024 was ¥564,522,598.46, down 6.58% year-on-year[2]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥518,796,572.39, a decline of 10.69% compared to the previous year[2]. - The basic earnings per share for Q3 2024 was ¥0.617, representing a decrease of 6.52% year-on-year[4]. - Total operating revenue for the first three quarters of 2024 was CNY 5,805,134,511.20, a decrease of 11.14% compared to CNY 6,536,764,954.98 in the same period of 2023[15]. - Net profit for the third quarter of 2024 was CNY 1,907,346,070.63, a slight decrease of 2.05% compared to CNY 1,947,379,873.64 in the third quarter of 2023[16]. - The total profit for the third quarter of 2024 was CNY 2,233,497,637.20, slightly down from CNY 2,259,575,656.87 in the third quarter of 2023[16]. Cash Flow - The net cash flow from operating activities for the year-to-date period decreased by 39.17% to ¥1,739,512,698.34[6]. - The net cash flow from operating activities was CNY 1,739,512,698.34, a decrease of 39.2% compared to CNY 2,859,639,142.08 in the previous year[18]. - Cash inflow from investment activities totaled CNY 2,745,625,237.74, down 32.0% from CNY 4,040,790,940.26 year-on-year[18]. - The net cash flow from investment activities was -CNY 2,076,597,588.57, compared to a positive CNY 406,529,472.64 in the same period last year[18]. - Cash inflow from financing activities amounted to CNY 1,159,785,934.41, an increase of 91.0% from CNY 606,496,858.78 in the previous year[19]. - The net cash flow from financing activities was -CNY 877,834,603.01, worsening from -CNY 409,080,913.88 year-on-year[19]. - The total cash and cash equivalents at the end of the period were CNY 6,523,063,316.84, down from CNY 7,676,028,547.73 at the end of the previous year[19]. - The company reported a total operating cash inflow of CNY 7,739,228,359.60, a decrease of 11.0% from CNY 8,683,452,611.32 in the previous year[18]. - Total cash outflow from operating activities was CNY 5,999,715,661.26, an increase of 3.0% compared to CNY 5,823,813,469.24 last year[18]. - The company received CNY 2,713,082,500.00 from investment recoveries, down 31.5% from CNY 3,957,703,350.26 in the previous year[18]. Assets and Liabilities - The total assets at the end of Q3 2024 were ¥18,151,776,184.80, showing a slight increase of 0.04% from the end of the previous year[4]. - The total assets of the company as of September 30, 2024, amounted to RMB 18,151,776,184.80, showing a slight increase from RMB 18,143,694,578.52 at the end of the previous period[14]. - The company's current assets totaled RMB 14,349,997,698.34, compared to RMB 14,235,429,851.57 in the previous period, indicating a growth of approximately 0.8%[12]. - The company's inventory increased from RMB 490,078,167.24 to RMB 663,699,165.37, reflecting a growth of approximately 35.3%[12]. - The total liabilities of the company decreased from RMB 4,774,832,070.86 to RMB 4,056,640,512.00, a reduction of about 15%[13]. - The company's retained earnings increased from RMB 8,847,776,002.96 to RMB 9,554,547,902.22, showing an increase of approximately 8%[14]. - The company’s total equity increased from RMB 13,368,862,507.66 to RMB 14,095,135,672.80, reflecting a growth of approximately 5.4%[14]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 40,113[7]. - The company approved a share repurchase plan with a total fund of no less than RMB 25 million and no more than RMB 50 million, with a maximum repurchase price of RMB 48 per share[10]. - As of September 30, 2024, the company has repurchased 180,500 shares, accounting for 0.02% of the total share capital, with a total payment of RMB 5,004,978[10]. Expenses - Research and development expenses for the first three quarters of 2024 were CNY 296,861,461.95, a decrease of 11.29% from CNY 334,603,477.50 in 2023[15]. - Sales expenses for the first three quarters of 2024 were CNY 2,190,344,923.91, down 19.43% from CNY 2,719,010,883.20 in the same period of 2023[15]. - The company experienced a financial expense of CNY -205,391,094.76 in the first three quarters of 2024, compared to CNY -170,305,263.86 in the same period of 2023[15]. Non-Recurring Items - The company reported non-recurring gains of ¥45,726,026.07 for the current period[5]. - The company has not adopted new accounting standards or interpretations affecting the financial statements for the year[20].